Pralsetinib 100mg Capsules for RET+ Thyroid & Lung Cancer

For treatment of thyroid cancer and non-small cell lung cancer (stages 1-3).

• Generic name: Platinib capsules
• Trade name: GAVRETO®
• English name: Pralsetinib Capsules
• Chinese Pinyin: Pulatini Jiaonang

Indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for rearrangement of transfection (RET) gene fusion and have previously received platinum-containing chemotherapy.

This indication was granted conditional approval based on study results in RET gene fusion-positive advanced NSCLC. Full approval depends on clinical benefit from ongoing confirmatory trials.

Learn more about Pralsetinib mechanism of action.

• Must be prescribed by a physician experienced in anti-tumor treatment
• Positive RET gene fusion must be confirmed before treatment
• Recommended dose: 400 mg orally once daily on empty stomach
• Continue treatment until disease progression or unacceptable toxicity

Most common adverse reactions (incidence ≥25%): constipation, hypertension, fatigue, musculoskeletal pain, and diarrhea.

Learn more about Pralsetinib side effects.

• Sealed and stored at ≤25℃
• After opening, keep in original packaging with desiccant